STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug
· statnews.com · popularity 32/100 · 0 similar stories today · Brain & Neuroscience (Discovery & Research)
Read the original at statnews.com →
Summary
Shares of ProMis Neurosciences, developer of a treatment for Alzheimer’s disease, sold off sharply last week. A closer look at the reason why — and whether it holds up.
Found in: STAT News. Rating basis: single outlet; outlet tier 4; 1 feeds; feed position 6.